VERICI DX PLC

Regulatory News Service • Nov 12, 2025

National Storage Mechanism | Additional information

RNS Number : 1171H

Verici Dx PLC

12 November 2025

Verici Dx plc

("Verici Dx" or the "Company")

Completion of CAP accreditation audit

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully completed its second biennial inspection of the Company's clinical laboratory, accredited by the College of American Pathologists ("CAP"). CAP is one of the leading US organisations for reviewing clinical laboratories and maintaining this accreditation is an essential part in continuing to implement the highest standards in clinical laboratory practice.

The inspection passed with no deficiencies, showing Verici Dx's commitment to compliance and maintaining excellence in daily clinical laboratory operations according to CAP requirements and their respective annual updates. By continuing to follow these strict CAP guidelines and pass CAP accreditation audits, Verici Dx can consistently provide reliable test results under its quality management system and further improve patient health.

Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said: "Verici Dx values the clinicians and patients that put their trust in our clinical laboratory, enabling a level of personalised care that has not been available to kidney transplant patients until now. We are dedicated to continuing to meet or exceed the regulatory requirements to be a trusted partner to clinicians."

Verici Dx plc	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Singer Capital Markets (Nominated adviser, Joint Broker)		Tel: +44 (0)20 7496 3000
Phil Davies / Sam Butcher
Oberon Capital (Joint Broker)	Tel: +44 (0)20 3179 0500
Mike Seabrook / Adam Pollock
Walbrook PR (Media & Investor Relations)	Tel: +44 (0)20 7933 8780 or [email protected]
Alice Woodings / Paul McManus	Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABBBATMTTBBLA